Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stannsoporfin in Neonates With Hyperbilirubinemia
NCT00850993Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Aug 2008
- Primary completion
- Jun 2011
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 4
01
Overview
A Phase 2 trial of stannsoporfin in neonatal hyperbilirubinemia, sponsored by Mallinckrodt Pharmaceuticals. Started Aug 2008; status: terminated.
02
Drugs
stannsoporfin
03
Conditions
neonatal hyperbilirubinemia
Beyond the preview
Go deeper on NCT00850993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00850993.